Login to Your Account

Other News To Note

Thursday, July 25, 2013

Prescience Labs LLC, of Potomac, Md., said the FDA has approved its investigational new drug application for Phase I clinical evaluation of its anti-cancer drug 3-bromopyruvate (PSL-001) in patients with primary and/or metastatic liver cancer. The study will evaluate the dosing regimen of the drug to determine the maximum tolerated dose based on the safety data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription